By Brandon Lowrey ( April 21, 2014, 10:13 PM EDT) -- A former Genta Inc. executive and two others agreed to pay penalties to resolve allegations of insider trading on confidential information about the now-defunct drugmaker's disappointing clinical tests for the experimental melanoma drug Genasense, the U.S. Securities and Exchange Commission announced Monday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.